The effect of haemodilution on antithrombin concentration was investigated in 73 patients undergoing elective cardiac surgery with and without cardiopulmonary bypass. In patients who required cardiopulmonary bypass (n=45), the antithrombin concentration fell to 52% of baseline during surgery (24.2 mg.dl -1 to 12.6 mg.dl -1 ), and the haemoglobin level fell to 55% (136 g.l -1 to 75 g.l -1 ). In patients who did not require cardiopulmonary bypass (n=28), the antithrombin concentration fell to 82% of baseline (23.7 mg.dl -1 to 19.5mg.dl -1 ), and the haemoglobin concentration fell to 78% (141 g.l -1 to 109 g.l -1 ). The overall correlation coefficient (r) for changes in antithrombin and haemoglobin concentrations was 0.76. The results indicate that most of the decrease in concentration of antithrombin during cardiac surgery is a consequence of cardiopulmonary bypass and is due to haemodilution. This data demonstrates that the percentage decrease in haemoglobin concentration can be used to estimate the percentage decrease in antithrombin concentration that occurs during cardiac surgery, if blood products that might effect the results are not administered between measurements.
Antithrombin (also known as antithrombin III 1 ) is a 58kDa serine protease inhibitor (serpin) that is a potent and important endogenous anticoagulant molecule. It can directly inhibit factor IIa (thrombin) as well as block factor IIa production by inhibiting other coagulation enzymes responsible for the generation of factor IIa. Antithrombin is capable of binding to and inhibiting factors IIa, Xa, IXa, XIa, XIIa, kallikrein, HMW kininogen and factor III:VIIa [2] [3] [4] . As with all serpins, antithrombin inhibits target enzymes using a "suicide-substrate" inhibition mechanism, with the formation of a covalent complex between the active serine site of the enzyme and the active site of antithrombin 5, 6 . This results in irreversible inhibition of both the coagulation enzyme and the antithrombin molecule. Thus, antithrombin is a major regulator of most serine proteases generated during contact and tissue factor activation of coagulation.
In the absence of heparin or heparan cofactors, antithrombin is an inefficient inhibitor of serine proteases. However, binding of a specific pentasaccharide unit of heparin or heparan sulphate introduces a conformational change in the antithrombin molecule 7-10 which potentiates serine protease inhibition over 1,000-fold through an allosteric mechanism 10 . It is by this mechanism that heparin exerts its potent anticoagulant effect during cardiac surgery.
In humans, antithrombin is distributed in three distinct physiological pools. Thirty-nine per cent of human antithrombin is located in the plasma, while 11% is in non-circulating vascular associated pools and 50% in an extravascular pool [11] [12] [13] . As much as 46% of the total vascular antithrombin pool is catabolized and replaced daily 11 . The capacity for and kinetics of movement of antithrombin between vascular and non-vascular pools has not yet been established.
Heparin is used to prevent thrombus formation during cardiac surgery. The anticoagulant action of heparin is dependent on an adequate concentration of antithrombin [7] [8] [9] [10] . Antithrombin concentrations decrease during cardiac surgery, particularly if cardiopulmonary bypass is used 14 . Currently, it is not known whether this decrease is caused by haemodilution alone (as a result of the administration of large volumes of fluid), or whether other factors, such as consumption of antithrombin, are involved [15] [16] [17] . The aim of the current study was to determine the relationship between changes in the concentrations of antithrombin and haemodilution in patients during cardiac surgery.
MATERIALS AND METHODS
With institutional approval and informed consent, 73 adult patients undergoing elective coronary artery bypass grafting were included in the study. Patients were divided into two groups depending on whether their surgery was performed with (ON-pump, n=45) or without (OFF-pump, n=28) cardiopulmonary bypass. The decision to perform the surgery with or without cardiopulmonary bypass was based on surgical factors alone, and was not influenced by inclusion in the study.
All patients received intravenous crystalloid solution at a rate of about 15 ml.kg -1 .hour -1 (approximately 1.0 l.hour -1 for most patients). Additional crystalloid solution (0.5 to 1.0 litre) was administered as required to increase cardiac filling pressures or replace blood loss. For ON-pump patients, the cardiopulmonary bypass circuit was primed with 2.3 litres of crystalloid solution. ON-pump patients also received 1 to 3 litres cardioplegic solution as part of their myocardial protection. All patients in the ON-pump group received a standard systemic loading dose of unfractionated porcine mucosal heparin (3 mg.kg -1 ) with a further 100 mg in the bypass prime. Additional heparin was administered as required to maintain an activated clotting time (ACT) >500 s during bypass. Hypothermic (28 to 32°C) cardiopulmonary bypass was established using standard uncoated PVC tubing (Lovell Surgical Supplies Pty Ltd, Australia), a hollow fibre oxygenator (Capiox SX18, Terumo®, Japan) and a 38 µm arterial filter (Affinity, Medtronic Inc, U.S.A.). Patients in the OFF-pump group received 100 mg of unfractionated porcine mucosal heparin (approximately 1.5 mg.kg -1 ) prior to grafting.
Blood samples for determination of antithrombin were drawn from a non-heparinized central venous catheter and placed into silicon coated glass collection tubes containing 1 part 0.105M trisodium citrate per 9 parts blood (Vacutainer™, Becton Dickinson, U.S.A.). A two-syringe technique was used, whereby the first 5 ml collected was discarded. Baseline samples were collected prior to induction of anaesthesia. For ON-pump patients, the second sample was collected three to five minutes after the commencement of extracorporeal circulation. For OFF-pump patients the second sample was collected at the commencement of the first distal coronary anastomosis. No patients received blood products between sample points.
The citrated blood samples were centrifuged at 2,000 G for 30 minutes at 15°C and the plasma phase removed for analysis. Plasma was tested within one hour of collection for antithrombin concentration. The concentration of antithrombin was determined using a commercially available rate nephelometric assay (Immage ® AT3, Beckman Coulter, Australia). Plasma was incubated with polyclonal goat antihuman antithrombin antibody and the rate of increase in light scatter by nephelometry was read against a standard curve for the concentration of antithrombin. The reference range for antithrombin in citrate plasma is 23-36 mg.dl -1 (Immage® Package Insert).
Whole blood samples for haemoglobin (Hb) measurement were collected from the same sample site at the same timepoints as the antithrombin samples. Hb concentration was determined within three to five minutes at the point of care using a portable haemoglobinometer (HemoCue AB, Sweden). This automated device mixes 250 µl whole blood with 50 µl of buffer (18% (w/v) sodium azide, 20% (w/v) sodium nitrite, 40% (w/v) sodium desoxycholate) in a cuvette to lyse erythrocytes and convert Hb to azide-methaemoglobin. Absorbency was measured at 570 nm and 880 nm. The concentration of Hb was read from a standard curve and displayed in digital form [18] [19] [20] .
The mean decrease of antithrombin and Hb concentrations were calculated for all patients, as well as for the ON-pump and OFF-pump sub-groups. The Hb and antithrombin concentration between ONpump and OFF-pump groups was compared using two-sided, unpaired t-tests. The intraoperative values were compared to preoperative values using onesided, paired t-tests. The Pearson correlation coefficient (r) for the decrease in Hb and antithrombin concentration was calculated with 95% confidence and the probability of no correlation (P) determined for all patients (n=73) as well as both subgroups. A P value of <0.05 was taken to be significant 21 .
RESULTS
Baseline Hb and antithrombin concentrations were in the normal range for all patients ( Table 1 ). The ON-pump and OFF-pump groups were similar in regard to age, weight, gender, baseline Hb, and antithrombin levels (Tables 1 and 2 ). In patients who required cardiopulmonary bypass (ON-pump, n=45) the antithrombin concentration decreased to 52% of baseline (from 24.2 mg.dl -1 to 12.6 mg.dl -1 , P<0.01), and Hb to 55% (from 136 g.l -1 to 75 g.l -1 , P<0.01). In patients who did not require cardiopulmonary bypass (OFF-pump, n=28) the antithrombin concentration decreased to 82% of baseline (from 23.7 mg.dl -1 to 19.5 mg.dl -1 , P<0.01), and the Hb to 78% (from 141 g.l -1 to 109 g.l -1 , P<0.01). The overall correlation coefficient (r) between changes in antithrombin and Hb concentrations was 0.76 with 95% confidence intervals of 0.64 to 0.85. The probability of no correlation was <0.01 (Figure 1 ). For the ON-pump subgroup the r was 0.33 (0.01, 0.56) and a probability of no correlation of 0.04. The r for the OFF-pump sub-group was 0.44 (0.02, 0.73) and a probability of no correlation of 0.04.
DISCUSSION
The results demonstrate that there is a close relationship between decreases in antithrombin and Hb concentration during cardiac surgery. By studying patients undergoing surgery both OFF-pump and ON-pump the specific effect of cardiopulmonary bypass on antithrombin (and Hb) could be examined. similar to the percentage decreases in haemoglobin in all patients, whether or not their surgery was performed using cardiopulmonary bypass. These findings suggest that most of the decrease in antithrombin during cardiac surgery is due to the effects of haemodilution alone.
The agreement between any two measured variables depends not only on their true relationship, but also on the accuracy of their measurement. Most measurement techniques have some inherent variability, even if the technique is considered a "goldstandard". In the current study, the antithrombin measurement technique had a precision of ±4% in citrated plasma (i.e. 95% of measurements were within ±4% of the true value) (Immage ® Package Insert). The measurement of Hb using the HemoCue has a precision of approximately ±3% if venous (as opposed to capillary) blood samples are used 22 . The combination of the inherent errors in the measurement of antithrombin and Hb must limit the correlation between these two variables. Despite this limitation, their was significant correlation (r=0.76, P<0.01).
The decrease in Hb from baseline is an accurate measure of haemodilution where no red cells have been transfused. This is because Hb is found only in the intravascular space. The extent of haemodilution depends on the volume of intravenous fluid administered, the initial red blood cell mass, and the amount of blood lost during the procedure. Red blood cell mass is a function of the haematocrit and the blood volume, which is related to the patient's body weight. For any patient, the relationship between haematocrit and Hb level is relatively constant. Although the HemoCue is not a "gold standard" for measurement of Hb, it is nevertheless the most accurate method of measuring Hb rapidly at the point of care.
The results confirm the findings of several previous studies that have shown reductions in antithrombin during cardiac surgery 14, 23 . The results demonstrate that there are significant reductions in antithrombin during cardiac surgery, even without the use of cardiopulmonary bypass. Presumably this reduction is caused by dilution of intravascular antithrombin by the administration of crystalloid solution. The use of cardiopulmonary bypass is associated with a greater fall in antithrombin, presumably due to the additional haemodilution caused by the crystalloid in the bypass prime. The final reduction in antithrombin concentration may be substantial, often resulting in concentrations below the normal range. In the current study the mean weight of the patients studied was about 81 kg and the lowest baseline antithrombin was 17.0 mg.dl -1 . Further reductions to more clinically significant levels may occur in patients with lower body weights (and therefore lower blood volume). The close correlation between Hb and antithrombin during cardiac surgery suggests that either there is no increase in catabolism or mobilization of storage pools of antithrombin during cardiac surgery, or, that these two processes are enhanced similarly. Antithrombin is a large (58 kDa) protein and thus it is unlikely to move between extra-and intravascular pools rapidly enough to have a significant effect during cardiac surgery.
The implications of low levels of antithrombin during cardiopulmonary bypass are not known. However, it is possible that very low levels increase the potential for thrombosis 24, 25 . During cardiopulmonary bypass large doses of heparin are used to prevent thrombosis. Nevertheless, the efficacy of heparin may be reduced in the presence of low antithrombin levels, and additional antithrombin may be required to ensure adequate anticoagulation 26, 27 .
At present, antithrombin concentrations cannot be monitored during cardiac surgery due to the lack of a rapid assay. A surrogate marker of antithrombin may be helpful in predicting the concentration. The results of the current study suggest that decreases in Hb can be used as a surrogate marker (at least until such time as blood products are transfused). Specifically, the percentage decrease in antithrombin concentration is similar to the percentage decrease in Hb concentration. The Hb can be monitored rapidly and accurately at the point of care, providing an index of the amount of haemodilution, and an estimate of the antithrombin concentration. If the preoperative antithrombin concentration is known the following equation can be used to calculate the intraoperative antithrombin:
[Intraop antithrombin]= [Preop antithrombin] x [intraop Hb]/ [Preop Hb]
where the baseline antithrombin concentration is not known, a value at the lower end of the reference range (i.e. 23 mg.dl -1 ) should be assumed to ensure safety. It should be noted that the formula would not be relevant following the administration of exogenous antithrombin, either with fresh frozen plasma or antithrombin concentrate, or following transfusion of red blood cells.
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